Small intestinal gastrointestinal stromal tumor in a young adult woman: a case report and review of the literature by unknown
JOURNAL OF MEDICAL
CASE REPORTS
Manxhuka-Kerliu et al. Journal of Medical Case Reports 2014, 8:321
http://www.jmedicalcasereports.com/content/8/1/321CASE REPORT Open AccessSmall intestinal gastrointestinal stromal tumor in a
young adult woman: a case report and review of
the literature
Suzana Manxhuka-Kerliu1*, Vjollca Sahatciu-Meka2, Irma Kerliu3, Argjira Juniku-Shkololli4, Lloreta Kerliu3,
Mevlyde Kastrati1 and Vesa Kotorri1Abstract
Introduction: Gastrointestinal stromal tumor is the most common sarcoma of the gastrointestinal tract. We report a
case of gastrointestinal stromal tumor in a small intestine, initially suspected for leiomyosarcoma given that
gastrointestinal stromal tumors in young adult patients are limited due to their rarity.
Case presentation: A 30-year-old Caucasian ethnic Albanian woman from Kosovo presented with abdominal
pain, nausea and vomiting. Subsequently, the tumor was detected in her small intestine, as an infiltrating mass
approximately 10cm in diameter. The tumor was resected en bloc and duodenojejunal terminal-terminal anastomosis
was performed. The tumor was a large, bulky, intramural mass, with fish-flesh to tan-brown appearance, as well as with
foci of hemorrhage and necrosis. On histological examination the tumor showed transmural growth, deep infiltrative
pattern and malignant feature, with mitotic count >5 per 50 high-power field, dense cellularity with plump spindle
cells, and with eosinophilic cytoplasm within variably hyalinized and edematous stroma, skeinoid fibers (extracellular
collagen globules) and foci of hemorrhage. In addition, the tumor was composed of areas with epithelioid
morphology. The immunohistochemistry results showed high expression of proto-oncogene c-kit, CD117, CD34
and vimentin, whereas α-smooth muscle actin was focally positive. Desmin and S-100 protein were negative.
Conclusions: Gastrointestinal stromal tumor should be included in the differential diagnoses of intestinal
mesenchymal tumors presenting as a single mass in young female adults. Given that gastrointestinal stromal
tumors in young adults represent a more heterogeneous group than gastrointestinal stromal tumor in
pediatric cases, more effort should be made to investigate its pathogenesis and potentially more specific
treatment.
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Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the gastrointestinal
tract. GISTs originate from the interstitial cells of Cajal
(ICCs), which are dependent on stem cell factor receptor
interaction. Like GISTs, these cells express both KIT and
CD34 [1].
The ICCs form a complex cell network within the gas-
trointestinal tract wall where they function as a pacemaker* Correspondence: skerliu@hotmail.com
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article, unless otherwise stated.system. Expression of the c-kit proto-oncogene is essential
for the development of this system [2].
Both benign and malignant GISTs commonly show
losses in chromosomes 14 and 22 in cytogenetic studies
and by comparative genomic hybridization. Losses in 1p
and chromosome 15 have been shown less frequently.
Gains and high level amplifications occur in malignant
GISTs in 3q, 8q, 5p and Xp. A proportion of GISTs, more
commonly the malignant examples, show mutations in
the regulatory juxtamembrane domain (exon 11) of the
c-kit gene. These c-kit mutations have been shown to
represent gain-of-function mutations leading to ligand-d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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sine kinase and further the phosphorylation cascade that
leads to mitogenic activation [3].
Riccardo Ricci et al. represented the historical growth
in genotype and phenotype evidence on GIST since 1998
in its increasing complexity by building a graph, named
“GISTogram”, that visually conveys most of the features
characterizing GISTs and the probability for each of
them, either alone or in combination, to be observed in
a single GIST case [4].
Key elements of the consensus, as described here, are
the defining role of KIT immunopositivity in the diagnosis
of GIST. A proposed scheme for estimating metastatic
risk in these lesions, based on tumor size and mitotic
count, recognizes that it is probably unwise to use the de-
finitive term “benign” for any GIST, at least at the present
time [5].
Given that KIT is immunohistochemically negative
in a minority of GISTs, especially in platelet-derived
growth factor receptor alpha (PDGFRA) gene mutation-
harboring GISTs, mutational analyses of c-kit and PDGFRA
genes may be required for a definitive diagnosis of such
GISTs [6].
KIT mutations in GIST are clustered in four exons.
Most common are exon 11 (juxtamembrane domain) mu-
tations that include deletions, point mutations (affecting a
few codons), and duplications (mostly in the 3′ region).
Exon 9 mutations (5 to 10%) usually are 2-codon 502-503
duplications, and these occur predominantly in intestinal
versus gastric GISTs. Most mutations are somatic (in
tumor tissue only), however, patients with familial GIST
syndrome have constitutional KIT/PDGFRA mutations;
greater than 10 families have been reported worldwide
with mutations generally similar to those in sporadic
GISTs [7].
For completely resected primary GISTs, mitotic rate,
tumor size, and tumor location are important risk fac-
tors for recurrence. However, molecular markers for re-
currence are still lacking. In the immunohistochemically
validated cohort, aurora kinase A (AURKA) expression
was significantly higher in nongastric tumors than in gas-
tric tumors and was significantly correlated with Armed
Forces Institute of Pathology-Miettinen risk group. By
integrating bioinformatics and clinicopathological studies,
AURKA was identified as a marker for high-risk GIST [8].
GISTs are a paradigm for the development of person-
alized treatment for patients with cancer. The study of
drug-resistant tumors has advanced our understanding
of kinase biology, enabling the development of novel
kinase inhibitors. Not all CD117-positive GISTs harbor a
KIT mutation and vice versa. With the current know-
ledge, we know that the KIT-mutated GIST group is not
homogenous in terms of prognosis and tyrosine kinase
inhibitor sensitivity, depending on the specific mutationsite within the KIT gene. Further improvements in GIST
treatment may require targeting GIST stem cell popula-
tions and/or additional genomic events [9].
Current knowledge demonstrates that the presence of
kinase mutations in c-kit and PDGFRA and their loca-
lization within the gene sequence as well as the mutation
type are of great importance for planning appropriate
treatment [10].
Several studies have shown that response to imatinib
in patients with GIST mainly depends on the mutational
status of KIT or PDGFRA. Moreover, most if not all pa-
tients treated with imatinib for advanced GIST will sec-
ondarily develop progressive disease under treatment. In
the majority of cases, such progressions are the result of
acquired resistance due to occurrence of secondary c-kit
mutations, especially for GIST with primary exon 11 mu-
tations. Sunitinib is another approved drug and an inhibi-
tor of multiple tyrosine kinases including KIT, PDGFRA
as well as platelet-derived growth factor receptor beta and
vascular endothelial growth factor receptors which are
associated with angiogenesis [11-14].
Sunitinib treatment may be one of the most important
therapeutic options for unresectable imatinib-resistant
GIST [15-17].
The clinical activity of sunitinib, after the failure of
imatinib, is significantly influenced by both primary
and secondary mutations in the predominant patho-
genic kinases [18].
Most patients with GIST eventually develop clinical
resistance to imatinib and sunitinib. Imatinib and suniti-
nib resistance generally result from secondary mutations
in the KIT and/or PDGFRA kinase domains. Preclinical
studies suggest that imatinib- and sunitinib-resistant mu-
tations can be treated using more potent kinase inhibitors,
such as nilotinib, which inactivate the mutant kinase pro-
teins. Alternatively, the mutant kinase proteins can be tar-
geted using heat shock protein 90 inhibitors, which result
in degradation of activated KIT and/or PDGFRA, or using
KIT transcriptional repressors, such as flavopiridol [19].
In this case report we present a patient with GIST in
her small intestine, initially suspected for leiomyosarcoma,
given that GISTs in young patients (under 40 years) are
limited due to their rarity.
Case presentation
A 30-year-old Caucasian ethnic Albanian woman from
Kosovo presented with abdominal pain, nausea and
vomiting. Subsequently, a tumor was detected in her
small intestine (duodenojejunum), as an infiltrating mass
approximately 10cm in diameter that had infiltrated her
pancreatic capsule and radix mesentery. The tumor was
resected en bloc and a duodenojejunal terminal-terminal
anastomosis was performed. On histological examination,
differential diagnoses considered were leiomyosarcoma
Figure 2 Epithelioid differentiation with perinuclear and
cytoplasmic vacuolization. Hematoxylin and eosin stain, 20×.
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nosis of malignant GIST.
Macroscopic features
The tumor was large, bulky, 10cm in diameter, with tan-
brown appearance, as well as with massive hemorrhagic
necrosis and cyst formation.
Histological and phenotypic findings
On histological examination, the tumor showed trans-
mural growth, deep infiltrative pattern and malignant
feature; it was high risk according to Fletcher’s criteria
with mitotic count >5 per 50 high-power field (HPF),
dense cellularity with plump spindle cells with eosino-
philic cytoplasm within variably hyalinized edematous
stroma, skeinoid fibers (extracellular collagen globules)
and foci of hemorrhage and necrosis. In addition, the
tumor was composed of areas with epithelioid morph-
ology (Figures 1, 2 and 3). The immunohistochemistry
results showed high expression of proto-oncogene c-Kit
(CD117), CD34 and vimentin, whereas α-smooth muscle
actin was focally positive. Desmin and S-100 protein
were negative. Ki-67 expression showed low proliferative
index (10%), (Figures 4, 5, 6, 7 and 8).
Our final diagnosis was intestine GIST, with mixed
spindle and epithelioid morphology.
Discussion
Rare cancer issues including GIST have not yet been
explored in depth because of their low incidence. As a
result, epidemiological studies are unsuccessful in identi-
fying indisputable etiological risk factors [20-23].
GISTs are the most common tumors among gastro-
intestinal mesenchymal. GISTs are different from neuro-
genic tumors, leiomyomas and leiomyosarcomas in initialFigure 1 Intestinal submucosal gastrointestinal stromal tumor
with dense cellularity, short fascicles and whorls. Hematoxylin
and eosin stain, 4×.symptom, tumor location, biological behavior and immu-
nophenotype. Immunohistochemistry plays an important
role in differentiating GISTs from leiomyomas and neuro-
genic tumors.
The origin of Cajal cells and smooth muscle from a
common precursor cell, the hybrid of these two seen in
many GISTs, and the occurrence of GISTs in the omen-
tum and mesentery, suggest that cells from such origin
will more likely differentiate toward a Cajal cell pheno-
type. Electron microscopic observations showing hybrid
autonomic nerve and smooth muscle features in many
GISTs are also consistent with origin from a multipoten-
tial precursor cell [24].
The resemblance of histomorphological features of our
case to that of smooth muscle tumors as well as the pa-
tient’s age led us to suspect leiomyosarcoma.
However, immunohistochemistry is conclusive in de-
termining the histology of the tumor, based on proto-Figure 3 Spindle cell area of gastrointestinal stromal tumor
with nuclear pleomorphism. Hematoxylin and eosin stain, 40×.
Figure 4 CD117+ (proto-oncogene c-Kit) strong and diffuse
cytoplasmic staining, 20×.
Figure 6 CD34+ strong and diffuse membrane staining, 20×.
Manxhuka-Kerliu et al. Journal of Medical Case Reports 2014, 8:321 Page 4 of 7
http://www.jmedicalcasereports.com/content/8/1/321oncogene c-kit (CD117) and CD 34 positivity, resulting
in the final diagnosis of small intestinal malignant GIST.
Folgado et al. found KIT mutations in 50% of all 10
patients evaluated. Most cases had a poor prognosis either
according to Fletcher’s criteria or given the presence of
metastasis [25].
There is a publication based on the investigation of 82
males and 31 females, with a median age of 51 years.
The primary sites of GIST were small intestine, stomach
and others. The tumor diameter varied from 1 to 26cm.
Most common histology was spindle cell morphology
followed by mixed spindle cell and epithelioid morph-
ology. No statistically significant association was noted
between high risk (HR) Fletcher score, proliferation
index- Mib score >10, tumor size >10cm, and the risk of
recurrence [26].
A more favorable prognosis in duodenal GISTs is at-
tributed to a smaller size of the lesion, and a low mitotic
count [27].Figure 5 Vimentin+, strong immunoreactivity, 20×.Lv et al. consider that tumor sites and total number of
microscopic indicators are independent risk factors
associated with the prognosis of GIST [28].
Similarly, our case of small intestine GIST shows com-
bined spindle cell and epithelioid morphology, tumor
size >10cm, HR Fletcher score, Ki-67 around 10% and
without synchronous metastasis.
Anaplastic GIST, with pleomorphic cells and loss of
CD117, until recently have only been reported in patients
with chronic imatinib mesylate treatment. Dedifferentia-
ted GISTs arising de novo is a newly identified entity that
may prove to be difficult to diagnose. It was presented in
the case of a 52-year-old woman found to have a dediffer-
entiated GIST without prior imatinib mesylate therapy.
This case is the first reported dedifferentiated GIST arising
de novo from the small bowel, and at 30cm in greatest
diameter, the largest reported to date [29].
GISTs are mesenchymal tumors of the intestinal tract
that typically occur in adults over the age of 40 years.Figure 7 Smooth muscle actin− focal immunoreactivity of some
smooth muscle differentiated cells, 10×.
Figure 8 Ki-67 low proliferation index (10%), 40×.
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age of patients [30].
GISTs in younger (under 40 years) patients are rare
and not well characterized. Of the 10 GISTs in young
adults, half occurred in the small bowel and had spindle
cell morphology, and one case had lymph node metasta-
sis. KIT mutations were identified in seven cases, four in
exon 11 and three in exon 9. GISTs that occur in chil-
dren are a separate clinicopathologic and molecular sub-
set with predilection for girls, multifocal gastric tumors,
and wild-type KIT/PDGFRA genotype. In contrast, GISTs
in young adults are a more heterogeneous group, includ-
ing cases that resemble either the pediatric or the older
adult-type tumors [31].
Likewise, we present a young woman (under the age of
40 years) with small intestinal GIST, with c-kit’ mutation
as well as CD34 overexpression; it shows heterogeneous
morphology.
Studies on GISTs in young patients are limited due to
their rarity, and none have been conducted in Asian
populations. GISTs from patients under the age of 30
years were retrospectively reviewed and were analyzed for
clinicopathologic features, immunohistochemistry and
mutations for exon 9, 11, 13, and 17 of KIT gene and exon
12, 14, and 18 of PDGFRA gene. Two pediatric (<18-years
old) and 20 young adult (18- to 30-years old) cases of
GIST were found. Of the 20 GISTs in young adults, 12
(60%) were from extra-gastric locations (six duodenum,
five jejunum, and one esophagus), and 16 (80%) showed a
spindle cell morphology. Mutations of KIT or PDGFRA
genes were identified in 14 (78%) of the 18 cases. Com-
pared with cases of pediatric GIST, cases of young adults
with GIST are heterogeneous and share the characteristics
of both GISTS in pediatric and adult cases [32].
On morphological examination, our case shares char-
acteristics of GISTs with both pediatric and adult cases,
spindle cell and epithelioid histology.Shimomura et al. published a case of an 18-year-old
girl who presented with abdominal pain; a tumor was
subsequently detected in her jejunum. GISTs are rare in
pediatric populations and pediatric GISTs occur pre-
dominantly in females and are characterized by a multi-
focal gastric location and a wild-type phenotype for the
c-kit genes. The features of pediatric GISTs of the small
intestine have not yet been categorized and, to date, only
11 cases in patients younger than 18 years have been re-
ported. GISTs of the small intestine were expected to
show a better response to imatinib treatment than gastric
GISTs because of the alterations in the c-kit gene [33].
Correspondingly, our case even though not in the pedia-
tric population but in young adulthood, arises in a female
patient as a solitary tumor mass.
Peritoneal and hepatic metastases are the main routes
of spread of GIST. However, criteria to predict the site
and pattern of recurrence in individual cases are still
lacking.
Agaimy et al. retrospectively analyzed 67 consecutive
GISTs with complete gross descriptions to correlate ma-
croscopic patterns with clinical course. Primary endpoint
was the appearance of synchronous or metachronous
peritoneal disease. Type I tumors were predominantly
gastric and frequently had very low/low risk whereas
type II tumors were predominantly intestinal and often
of intermediate/high risk. The careful gross and micro-
scopic assessment of a resection specimen harboring
GIST is of great importance because it allows for reliable
prospective evaluation of serosal involvement as an
adverse prognostic factor in GIST [34].
Indistinguishably, based on the macroscopic/histologic
presence or absence of normal tissue between deeper
tumor border and serosa, respectively, our case belongs
to type II (extramural) high risk tumor, but without
synchronous or metachronous metastases.
Less than 5% of GISTs are KIT-immunonegative; many
of these tumors have activating mutations of PDGFRA,
some of which are also inhibited by imatinib. It is
becoming evident that alternative approaches to direct
KIT inhibition will be required for long-term survival of
patients with advanced GISTs [35].
Although rare, GISTs should be considered in the dif-
ferential diagnoses of perforated gastrointestinal masses.
Skipworth et al. presented the first English report of a
perforated gastric GIST. Six further published reports
describing the presentation of small bowel GISTs with
perforation are reviewed [36].
We describe a rare case of small intestinal GIST pre-
senting without perforation.
Boudabous et al. collected 24 cases of GIST (confirmed
by the positivity of CD117 and/or CD33) analyzing de-
mographic characteristics, clinical pattern, investigations
treatment and therapeutic variables of patients. In 13 out
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arising from muscular layer found in the stomach (54%),
small bowel in four cases (16.5%) and duodenal or rectum
in three patients (12.5%). The prognostic predictive factors
identified were the size of tumor ≥10cm and the mitotic
index [37].
Taking into account prognostic predictive factors found
in our case, such as the size of the tumor 10cm, high mi-
totic index >5 per 50 HPF as well as extramural growth,
there is a great chance of recurrence of the tumor.
Recent review articles focus on histopathologic criteria
but omit clinical features and course of disease. In non-
syndromal CD117-positive GIST, girls tend to show more
high-grade tumors and existing literature on pediatric
GIST shows a 2.7-fold higher incidence in females. Al-
together epithelioid cell tumors are most frequent,
although in boys spindle cell tumors are reported more
often. Together with known differences in molecular
changes and local as well as systemic tumor behavior
this strongly suggests that pediatric GIST represents a
different entity from adult GIST [38].
Belev et al. and Menéndez et al. investigated primarily
the prognostic value of Ki-67, as well as other parame-
ters, in GISTs. Ki-67 presents a significant prognostic
factor for GIST recurrence, which could be of great im-
portance in evaluating the malignant potential of disease
[39,40].
Our case shows a low proliferative index based on
Ki-67 expression (10%). No significant association was
noted between HR Fletcher score and Ki-67 score.
The standard therapy for GIST is complete surgical
resection with safety margins of 1 to 2cm. Patients can
achieve complete remission when thorough surgical
resection is performed. Moreover, incomplete resection,
including debulking surgery, does not seem to prolong
survival [41].
Morrison and Hodgdon reported two cases of patients
who were presented to an emergency department with
signs and symptoms of small bowel obstruction. The
pathologic diagnosis of small bowel GIST tumor was the
same in both cases. Each tumor had a different method
of obstruction, with one causing a volvulus and the other
an intraluminal obstruction; however, both were success-
fully removed laparoscopically [42].
Likewise, our case clinically caused gastrointestinal
hemorrhage and obstruction.
Conclusions
GIST should be included in the differential diagnoses of
intestinal mesenchymal tumors presenting as a single
mass in young female adults. Obstruction from GIST
tumors of the small bowel is a relatively rare occurrence,
but should be considered in the differential diagnosis
when other causes are not readily apparent and a solidlesion is demonstrated in the small bowel. Fletcher’s cri-
teria are a useful prognostic classification because when
applicable they are consistent with the evolution and
prognosis of disease. Given that GIST in young adults
(under 40 years of age) represents a more heterogeneous
group, than GIST in pediatric cases, more effort should
be made to investigate its pathogenesis and potentially
more specific treatment.
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